In fiscal 2026, which ended Jul 31, 2026, Briacell Therapeutics Corp. used $28.7 million of cash from operations, down 1.7% from the year before. It spent $127,049 on capital expenditures. Free cash flow was negative, at -$28.8 million.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jul 31, 2026
|
FY 2025
Jul 31, 2025
|
FY 2024
Jul 31, 2024
|
FY 2023
Jul 31, 2023
|
FY 2022
Jul 31, 2022
|
FY 2021
Jul 31, 2021
|
|---|---|---|---|---|---|---|
| Operating | ||||||
| Depreciation and amortization |
0
+13.9%
|
0
+33.1%
|
0
|
—
|
0
+0.1%
|
0
|
| Stock-based compensation |
1
+72.1%
|
1
-63.6%
|
2
-17.8%
|
2
-28.6%
|
3
+56.2%
|
2
|
| Operating cash flow |
-29
-1.7%
|
-28
-16.8%
|
-24
-1.6%
|
-24
-90.2%
|
-12
-61.1%
|
-8
|
| Investing | ||||||
| Capital expenditures |
0
-72.2%
|
—
|
0
|
—
|
—
|
—
|
| Investing cash flow |
-4
+50.2%
|
-8
-1021.4%
|
-1
|
—
|
—
|
—
|
| Financing | ||||||
| Debt issued |
—
|
—
|
—
|
—
|
—
|
0
|
| Debt repaid |
—
|
—
|
—
|
—
|
—
|
0
|
| Short-term debt repaid |
—
|
—
|
—
|
—
|
—
|
0
|
| Stock buybacks |
—
|
—
|
—
|
0
-99.5%
|
10
|
—
|
| Financing cash flow |
32
-30.0%
|
45
+928.5%
|
4
+11.7%
|
4
+205.7%
|
-4
-105.8%
|
65
|
| Change in cash | ||||||
| Net change in cash |
-1
-106.7%
|
10
+147.2%
|
-20
|
—
|
—
|
—
|
| Free cash flow |
-29
-0.5%
|
—
|
-25
|
—
|
—
|
—
|
| Per share | ||||||
| Free cash flow per share |
-5.74
+91.5%
|
—
|
-224.09
|
—
|
—
|
—
|
| Shareholder returns | ||||||
| Returned to shareholders |
—
|
—
|
—
|
0
|
10
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BCTX (Nasdaq), BCTXL (Nasdaq), BCTXZ (Nasdaq)
- Fiscal year ends
- July 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- West Vancouver, British Columbia, Canada
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1610820
- Former names
- Ansell Capital Corp. (until Jun 20, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.